Welcome to our dedicated page for Roivant Sciences news (Ticker: roivw), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roivant Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roivant Sciences's position in the market.
Roivant Sciences Ltd. (Nasdaq: ROIV) reported financial results for Q2 2022, emphasizing a strong performance from VTAMA with $5.0 million in revenue from over 54,000 prescriptions. The company announced its first major PBM contract, improving access to VTAMA. Cash runway has been extended into H2 2025, supported by recent capital infusions totaling $150 million. Roivant also highlighted progress in its immunology pipeline, including the completion of enrollment for a registrational trial for brepocitinib in lupus. However, a net loss of $315.9 million was reported for the quarter.
Affivant, a biotechnology company, will present a poster on AFVT-2101 at the 37th Annual Meeting of SITC on November 11, 2022. AFVT-2101 is an Innate Cell Engager designed to target folate receptor alpha on tumors, facilitating immune cell activation for tumor destruction. The poster reports findings that AFVT-2101 effectively binds to CD16A, induces potent antibody-dependent cellular cytotoxicity (ADCC), and shows minimal off-target effects. The study confirms AFVT-2101's potential as a safe and powerful therapy in preclinical settings.
Roivant Sciences announced the pricing of a public offering of 30 million common shares at $5.00 each, generating gross proceeds of $150 million. Roivant will receive approximately $100 million from the offering, while selling shareholders will obtain about $50 million. The underwriter has a 30-day option for an additional $22.5 million in shares. The offering is set to close on November 10, 2022, subject to conditions. Roivant expects its cash flow to sustain operations into the second half of 2025.
Roivant Sciences announced a proposed underwritten public offering of $150 million of common shares, with a 30-day option for the underwriter to purchase an additional $22.5 million. The offering is subject to market conditions, with no assurance on its completion or terms. Cantor Fitzgerald & Co. is the sole bookrunner for this offering. A registration statement for these securities was declared effective on October 3, 2022, and a preliminary prospectus supplement has been filed with the SEC. This announcement does not constitute an offer to sell securities.
Roivant Sciences (Nasdaq: ROIV) will host a conference call on November 14, 2022, at 8:00 a.m. EST to discuss its financial results for Q2 ended September 30, 2022, alongside a corporate update. The company is also participating in several investor conferences in November, including the Credit Suisse Annual Healthcare Conference and Jefferies London Healthcare Conference. Presentations by CFO Richard Pulik and CEO Matt Gline will provide insights on Roivant's strategic initiatives and outlook. Archived webcasts will be accessible on Roivant's investor website post-event.
Roivant Sciences (Nasdaq: ROIV) will participate in three healthcare investor conferences this September in Boston, New York, and London. The schedule includes:
- Citi BioPharma Conference in Boston on September 7
- H.C. Wainwright Global Investment Conference in New York on September 12, with CEO Matt Gline presenting at 8:30 a.m. EDT
- Bank of America Global Healthcare Conference in London on September 16
Additionally, Roivant will host a virtual Investor Day on September 28 at 11:00 a.m. EDT.
Roivant Sciences reported strong early demand for VTAMA, with 14,000 prescriptions in the first 11 weeks post-launch, marking it as the top prescribed topical for psoriasis in the US. The company announced a net loss of $353.8 million for Q1 2022, up from $101.1 million in Q1 2021. R&D expenses increased to $135.8 million, and SG&A expenses rose to $149.1 million, largely due to heightened share-based compensation. The ongoing trials for brepocitinib and tapinarof are progressing well, with data expected in late 2023. Investor day scheduled for September 28 will provide further updates.
Roivant Sciences (Nasdaq: ROIV) announced an investor call and webcast on August 15, 2022, at 8:00 a.m. EDT, to discuss its financial results for Q1 ended June 30, 2022, and provide a corporate update. Additionally, an investor day is scheduled for September 28, 2022, at 11:00 a.m. EDT, to offer updates on Roivant and its subsidiaries, known as Vants. The company aims to improve healthcare delivery and develop transformative medicines more efficiently. The press release serves as a reminder for both events, intended for investor engagement and transparency.
Roivant Sciences has reported significant developments and financial results for the fiscal year ending March 31, 2022. The FDA approved VTAMA (tapinarof) for plaque psoriasis, marking a milestone as the first new chemical entity in 25 years. With $2.1 billion in cash, Roivant prioritizes its pipeline and has initiated a strategic review, discontinuing non-essential programs to focus on high-value opportunities. Research and development expenses increased significantly, amounting to $483 million. Despite challenges, the company remains positioned for growth with ongoing trials and a robust commercial strategy.
Priovant Therapeutics, a collaboration between Roivant Sciences and Pfizer, is focusing on developing brepocitinib, a first-in-class dual inhibitor targeting TYK2 and JAK1. Earlier this quarter, a Phase 3 trial for dermatomyositis (VALOR) was initiated, while a Phase 2b study for systemic lupus erythematosus (SLE) is expected to yield results in the second half of 2023. Brepocitinib has shown statistically significant results in five prior placebo-controlled studies. The need for effective therapies in severe autoimmune diseases underscores the potential of brepocitinib in clinical treatments.